CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765)

Market Cap	31.56B
Revenue (ttm)	2.13B
Net Income (ttm)	627.69M
Shares Out	1.40B
EPS (ttm)	0.46
PE Ratio	49.54
Forward PE	61.08
Dividend	0.27 (1.17%)
Ex-Dividend Date	Apr 25, 2024

Volume	3,665,986
Open	24.18
Previous Close	22.83
Day's Range	22.24 - 24.18
52-Week Range	9.94 - 40.62
Beta	-0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2024

About CSPC Innovation Pharmaceutical

CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, APIs, and functional foods in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and raw enzymes; and health food products, such as Guoweikang Vitamin C tablets, Guoweikang B vitamin lozenges, etc. The company was founded in 2006 and is headquartered in Shijiazhuang, Ch...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2006
• Employees: 1,887
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300765

Financial Performance

In 2023, CSPC Innovation Pharmaceutical's revenue was 2.50 billion, a decrease of -4.75% compared to the previous year's 2.63 billion. Earnings were 755.56 million, an increase of 4.03%.